348 related articles for article (PubMed ID: 25770211)
21. Expression of Melatonin and Dopamine D
Reyes-Resina I; Awad Alkozi H; Del Ser-Badia A; Sánchez-Naves J; Lillo J; Jiménez J; Pintor J; Navarro G; Franco R
Cells; 2020 Jan; 9(1):. PubMed ID: 31936298
[TBL] [Abstract][Full Text] [Related]
22. Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2.
Söderquist F; Hellström PM; Cunningham JL
PLoS One; 2015; 10(3):e0120195. PubMed ID: 25822611
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
24. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
25. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
Millan MJ; Gobert A; Lejeune F; Dekeyne A; Newman-Tancredi A; Pasteau V; Rivet JM; Cussac D
J Pharmacol Exp Ther; 2003 Sep; 306(3):954-64. PubMed ID: 12750432
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of the ligand binding and signaling mechanism of melatonin receptors.
Wang Q; Lu Q; Guo Q; Teng M; Gong Q; Li X; Du Y; Liu Z; Tao Y
Nat Commun; 2022 Jan; 13(1):454. PubMed ID: 35075127
[TBL] [Abstract][Full Text] [Related]
27. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
28. XFEL structures of the human MT
Johansson LC; Stauch B; McCorvy JD; Han GW; Patel N; Huang XP; Batyuk A; Gati C; Slocum ST; Li C; Grandner JM; Hao S; Olsen RHJ; Tribo AR; Zaare S; Zhu L; Zatsepin NA; Weierstall U; Yous S; Stevens RC; Liu W; Roth BL; Katritch V; Cherezov V
Nature; 2019 May; 569(7755):289-292. PubMed ID: 31019305
[TBL] [Abstract][Full Text] [Related]
29. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Millan MJ
Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
[TBL] [Abstract][Full Text] [Related]
30. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
31. Melatonin receptor heterodimerization in a photoreceptor-like cell line endogenously expressing melatonin receptors.
Sánchez-Bretaño A; Suen TC; Baba K; DeBruyne J; Tosini G
Mol Vis; 2019; 25():791-799. PubMed ID: 31819341
[TBL] [Abstract][Full Text] [Related]
32. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
33. Major depressive disorder, anhedonia and agomelatine: an open-label study.
Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
[TBL] [Abstract][Full Text] [Related]
34. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.
Chagraoui A; Protais P; Filloux T; Mocaër E
Psychopharmacology (Berl); 2003 Oct; 170(1):17-22. PubMed ID: 12904965
[TBL] [Abstract][Full Text] [Related]
35. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.
Boiko DI; Shkodina AD; Hasan MM; Bardhan M; Kazmi SK; Chopra H; Bhutra P; Baig AA; Skrypnikov AM
Neurochem Res; 2022 Oct; 47(10):2909-2924. PubMed ID: 35689787
[TBL] [Abstract][Full Text] [Related]
36. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
[TBL] [Abstract][Full Text] [Related]
37. Nociceptive responses in melatonin MT
Posa L; Lopez-Canul M; Rullo L; De Gregorio D; Dominguez-Lopez S; Kaba Aboud M; Caputi FF; Candeletti S; Romualdi P; Gobbi G
J Pineal Res; 2020 Oct; 69(3):e12671. PubMed ID: 32430930
[TBL] [Abstract][Full Text] [Related]
38. Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT
Oishi A; Karamitri A; Gerbier R; Lahuna O; Ahmad R; Jockers R
Sci Rep; 2017 Aug; 7(1):8990. PubMed ID: 28827538
[TBL] [Abstract][Full Text] [Related]
39. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
40. GW117: A novel serotonin (5-HT
Gao N; Zheng W; Murezati T; Gu W; Li X; Jin Z
CNS Neurosci Ther; 2021 Jun; 27(6):702-713. PubMed ID: 33650297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
